Posts by Andrew Mahoney
4 Takeaways from the 2023 NORD Rare Diseases and Orphan Products Breakthrough Summit
Last week, Bobby Moy, managing director of Clarion, a Lumanity business, attended the NORD 2023 Rare Diseases and Orphan Products Breakthrough Summit in Washington DC. Here, he shares four key takeaways from the conference. At Clarion, we understand the critical importance of patient-centricity, regulatory adaptability, diversity, and understanding the intricacies of patients’ lives in the…
Read More4 Top Takeaways from ASGCT’s 26th Annual Meeting
Last week, Bobby Moy, managing director of Clarion, a Lumanity business, attended the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles, California. Here, he shares four key takeaways from the conference: Are you a company that is looking for guidance in the rare disorder and/or gene therapy…
Read MoreBridging the Gap in Translation and Innovation: Oncology’s PoS Problem
By: Dennis Chang Oncology drug development has produced remarkable breakthroughs in the last decade, including various immunotherapies and precision medicine approaches, offering hope for previously incurable cancers. However, the probability of success (PoS) in oncology is among the lowest of all therapeutic areas: the likelihood of regulatory approval for programs entering Phase 1 is only…
Read More